Eli Lilly and Company (NYSE:LLY) Shares Sold by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 15.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,614 shares of the company’s stock after selling 10,035 shares during the period. Eli Lilly and Company makes up 1.9% of Braun Stacey Associates Inc.’s investment portfolio, making the stock its 7th largest holding. Braun Stacey Associates Inc.’s holdings in Eli Lilly and Company were worth $49,271,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. PAX Financial Group LLC lifted its holdings in shares of Eli Lilly and Company by 3.4% in the 1st quarter. PAX Financial Group LLC now owns 458 shares of the company’s stock worth $356,000 after purchasing an additional 15 shares in the last quarter. Point Break Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 75.9% in the 1st quarter. Point Break Capital Management LLC now owns 2,401 shares of the company’s stock worth $1,868,000 after purchasing an additional 1,036 shares in the last quarter. Hilltop Partners LLC lifted its holdings in shares of Eli Lilly and Company by 7.9% in the 1st quarter. Hilltop Partners LLC now owns 975 shares of the company’s stock worth $758,000 after purchasing an additional 71 shares in the last quarter. Capitolis Liquid Global Markets LLC bought a new position in shares of Eli Lilly and Company in the 1st quarter worth $86,665,000. Finally, Atlanta Consulting Group Advisors LLC bought a new position in shares of Eli Lilly and Company in the 1st quarter worth $365,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 5.1 %

Shares of NYSE:LLY opened at $746.20 on Monday. The company has a market cap of $708.38 billion, a P/E ratio of 80.67, a PEG ratio of 2.82 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The stock’s fifty day moving average price is $882.65 and its 200-day moving average price is $871.04.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the prior year, the company posted $0.10 EPS. The firm’s revenue was up 20.4% compared to the same quarter last year. Sell-side analysts expect that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is 56.22%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on LLY shares. Wolfe Research started coverage on Eli Lilly and Company in a report on Friday. They issued an “outperform” rating and a $1,000.00 target price on the stock. Barclays decreased their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Bank of America dropped their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. Finally, Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target on the stock. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,007.94.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.